Allarity Granted Hearing Before Nasdaq Panel To Present Plan Of Regaining Compliance
Portfolio Pulse from Benzinga Newsdesk
Allarity Therapeutics (NASDAQ:ALLR) has been granted a hearing before a Nasdaq Hearings Panel to present its plan for regaining compliance with NASDAQ listing requirements.
June 27, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Allarity Therapeutics has been granted a hearing before a Nasdaq Hearings Panel to present its plan for regaining compliance with NASDAQ listing requirements.
The hearing provides Allarity Therapeutics an opportunity to present its plan to regain compliance with NASDAQ listing requirements. This news is crucial for the company's stock as it directly impacts its listing status, but the outcome of the hearing is uncertain, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100